Current Report Filing (8-k)
September 08 2017 - 8:32AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 8, 2017
RESPIRERX
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
1-16467
|
|
33-0303583
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S
Employer
Identification No.)
|
126
Valley Road, Suite C
Glen
Rock, New Jersey
|
|
07452
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (201) 444-4947
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
7.01 Regulation FD Disclosure
On
September 8, 2017, RespireRx Pharmaceuticals Inc. (the “Company”) announced that the Company’s President, Chief
Executive Officer and Vice Chairman of the Board of Directors James S. J. Manuso, Ph.D., will be presenting at the 2017 Rodman
& Renshaw Conference at The Palace Hotel, New York, New York. Dr. Manuso is currently scheduled to present at 1:45 p.m. Eastern
Time on Tuesday, September 10, 2015.
Dr.
Manuso will discuss RespireRx’s successfully completed Phase IIB clinical trial of dronabinol in the treatment of obstructive
sleep apnea, and will present the results of a Phase IIA trial evaluating the ability of CX-1739 (oral) to antagonize the drug-induced
respiratory depression produced by the powerful opioid, remifentanil. He will also provide updated information and clinical development
plans for the company’s pipeline products.
The
slide presentation that Dr. Manuso will be using at the conference is attached as Exhibit 99.1 and is being furnished and not
filed pursuant to Item 7.01 of Form 8-K. The presentation will be available by live webcast and will be archived. The live webcast
and archive can be accessed by going to:
http://wsw.com/webcast/rrshq27/rspi
The
press release announcing the Company’s participation in the conference is attached as Exhibit 99.2 to this Current Report
on Form 8-K.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits.
A
list of exhibits required to be filed as part of this report is set forth in the Exhibit Index, which is presented elsewhere in
this document, and is incorporated herein by reference.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
September 8, 2017
|
RESPIRERX
PHARMACEUTICALS INC.
|
|
(Registrant)
|
|
|
|
|
By:
|
/s/
Jeff E. Margolis
|
|
|
Jeff
E. Margolis
|
|
|
Vice
President, Treasurer and Secretary
|
EXHIBIT
INDEX
*
Furnished herewith.
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Apr 2023 to Apr 2024